藥品參考
Eltrombopag
Eltrombopag is a medicine in the class miscellaneous. It is used for aplastic anemia.
- 藥物類別: Miscellaneous
- 用途: aplastic anemia
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Miscellaneous
- ATC 代碼
- B02BX05
- 常見劑型
- 錠劑, 口服懸液
- 常見規格
- 50 mg, 25 mg
- 已知交互作用
- 124 (中度: 66 · 輕微: 58)
- 商品名
- 14
- 國家與市場
- 5
用途
作用方式
Small-molecule thrombopoietin (TPO)-receptor agonist that interacts with human TPO receptor transmembrane domain of human TPO-receptor & initiates signaling cascades that induce proliferation & differentiation of megakaryocytes from bone marrow progenitor cells
成人常用劑量（仿單摘要）
Chronic Immune Thrombocytopenia (ITP): Initial: 50 mg PO qDay, Adjust dose to achieve and maintain platelet count (Plt) >50 x 10^9/L to reduce risk of bleeding; not to exceed 75 mg/day.
懷孕與哺乳
- 懷孕
- Unknown Case reports are too few to assess risk; in rats, maternally toxic doses caused embryo death and lower fetal weight. EU label: not recommended in pregnancy or in women not using contraception. Use effective contraception during and for 7 days after treatment.
- 哺乳
- Unsafe No human milk data; it reached rat pups through milk. US label: breastfeeding not recommended. It clears about 8 days after the last dose. LactMed: one infant had prolonged high platelets; if used, monitor the infant's blood counts.
已通報的副作用
- Headache
- Fatigue
- Upper respiratory tract infection
- Nasopharyngitis
- Nausea
- Anemia
哪些人需要特別留意
- May develop or worsen cataracts; screen before administering and during treatment
- Thrombotic/thromboembolic complications reported; have included both venous and arterial events and were observed at low and at normal platelet counts.
- Portal vein thrombosis reported in patients with chronic liver disease receiving therapy
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (124)
- Alpelisib + Eltrombopag Moderate
- Aluminum hydroxide + Eltrombopag Moderate
- Amobarbital + Eltrombopag Moderate
- Artesunate + Eltrombopag Moderate
- Atazanavir + Eltrombopag Moderate
- Atorvastatin + Eltrombopag Moderate
- Berotralstat + Eltrombopag Moderate
- Butabarbital + Eltrombopag Moderate
- Butalbital + Eltrombopag Moderate
- Calcium + Eltrombopag Moderate
常見問題
What is Eltrombopag used for?
Eltrombopag is a medicine in the class miscellaneous. It is used for Aplastic anemia, Thrombocytopenia.
What side effects have been reported with Eltrombopag?
Headache, Fatigue, Upper respiratory tract infection, Nasopharyngitis, Nausea, Anemia.
Can Eltrombopag be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. Case reports are too few to assess risk; in rats, maternally toxic doses caused embryo death and lower fetal weight. EU label: not recommended in pregnancy or in women not using contraception. Use effective contraception during and for 7 days after treatment. Breastfeeding: Unsafe. No human milk data; it reached rat pups through milk. US label: breastfeeding not recommended. It clears about 8 days after the last dose. LactMed: one infant had prolonged high platelets; if used, monitor the infant's blood counts.
What does Eltrombopag interact with?
MediHelp lists 124 known interactions for Eltrombopag. Moderate: 66 · Minor: 58. The most serious include Alpelisib, Aluminum hydroxide, Amobarbital.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
